zoranmEyePoint (NASDAQ:EYPT) has a potential blockbuster with EYP-1901 after a successful P2 trial that met all its endpoints in a very promising development. It sold off its remaining drug YUTIQ and reverted to a pure development company, betting the bank on EYP-1901. EYP-1901 has three possible uses (Wet AMD, NPDR and DME) each of which are multi-billion dollar markets, but after rising 400%+ in less than a year, the stock isn't a home run anymore and risks remain.  FinVizA quick recap, the company de ...